For example, during the phase 2a study for DSM265, a novel Plasmodium dihydroorotate dehydrogenase (DHODH) inhibitor, point mutations in the dhodh gene sufficient to cause DSM265 resistance, and a likely gene amplification surrounding the gene were identified in patients with recurrent infections.14 This emphasizes the importance of using DSM265 in combination therapy with another antimalarial drug to minimize the development of resistance. This evidence concerns the gene DHODH and infection.